secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-117219
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute Q1 FY2024 net loss $14.5M; RZ358 Phase 3 start planned before year-end
-------------------------------------------------------------------------------

- Net loss of $14.5M for Q1 FY2024 vs $9.8M in same period last year.
- R&D expenses $12.2M (up 58% YoY) due to increased clinical and manufacturing costs.
- Cash and investments $106.9M as of Sep 30, 2023, down from $118.4M at Jun 30, 2023.
- RZ358 granted EMA PRIME designation; Phase 3 sunRIZE study for congenital hyperinsulinism to initiate Q4 2023.
- RZ402 Phase 2 enrollment in diabetic macular edema near completion; update expected before year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923117219/0001104659-23-117219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923117219/tm2330300d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-117219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer